LAVA Therapeutics NV (LAVA Therapeutics NV) Gross-Profit-to-Asset % : 27.86% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LAVA Therapeutics NV's annualized Gross Profit for the quarter that ended in Mar. 2024 was $27.97 Mil. LAVA Therapeutics NV's average Total Assets over the quarter that ended in Mar. 2024 was $100.39 Mil. Therefore, LAVA Therapeutics NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 27.86%.

LAVA Therapeutics NV Gross-Profit-to-Asset % Historical Data

The historical data trend for LAVA Therapeutics NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Gross-Profit-to-Asset % Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

25.59

6.70

13.72

2.68

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial													0.84	8.54	0.15	0.75	27.86

Competitive Comparison of LAVA Therapeutics NV's Gross-Profit-to-Asset %

For the Biotechnology subindustry, LAVA Therapeutics NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's Gross-Profit-to-Asset % falls into.

LAVA Therapeutics NV Gross-Profit-to-Asset % Calculation

LAVA Therapeutics NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	3.287	/	( (143.425	+	101.71)	/ 2 )
	=	3.287	/	122.5675
	=	2.68 %

LAVA Therapeutics NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	27.968	/	( (101.71	+	99.079)	/ 2 )
	=	27.968	/	100.3945
	=	27.86 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

LAVA Therapeutics NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.